Tomasik Bartłomiej, Garbicz Filip, Braun Marcin, Bieńkowski Michał, Jassem Jacek
Department of Oncology and Radiotherapy, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland.
Department of Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.
Camb Prism Precis Med. 2023 Oct 5;2:e2. doi: 10.1017/pcm.2023.23. eCollection 2024.
Precision oncology is a rapidly evolving concept that holds great promise in cancer treatment. However, a cancer complexity attributed to genomic and acquired tumour heterogeneity limits treatment effectiveness and increases toxicity. These limitations refer to both systemic therapies and radiotherapy, which are two mainstays of non-invasive cancer treatment. By understanding cancer heterogeneity and utilising advanced tools to personalise treatment strategies, precision oncology has the potential to revolutionise cancer care. In this article, we review the current status of precision oncology in solid tumours, specifically focusing on the impact of tumour heterogeneity and genomic patient features on systemic therapies and radiation. We also discuss the implementation of novel tools, such as next-generation sequencing and liquid biopsies, to overcome this problem.
精准肿瘤学是一个快速发展的概念，在癌症治疗中具有巨大潜力。然而，由基因组和获得性肿瘤异质性导致的癌症复杂性限制了治疗效果并增加了毒性。这些限制既适用于全身治疗，也适用于放射治疗，而这两者是非侵入性癌症治疗的两大支柱。通过了解癌症异质性并利用先进工具来个性化治疗策略，精准肿瘤学有潜力彻底改变癌症护理。在本文中，我们回顾了实体瘤中精准肿瘤学的现状，特别关注肿瘤异质性和基因组患者特征对全身治疗和放疗的影响。我们还讨论了新一代测序和液体活检等新型工具的应用，以克服这一问题。
